Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Maintains Buy Rating for Nutrien with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
February 1, 2024
in Breaking News
0
Finance_Budgeting (1)
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

On February 1, 2024, Adam Samuelson, an analyst at Goldman Sachs, reaffirmed his positive sentiment towards Nutrien (NTR) by maintaining a Buy rating. However, he did make an adjustment to the price target, lowering it from $88 to $78. This adjustment aligns with the median target of $75.00 suggested by a group of 23 analysts.

Although the price target has decreased, the Buy rating still signifies an optimistic outlook for Nutrien’s stock. It is crucial for investors to take into account the diverse range of analyst recommendations and price targets in order to make well-informed investment decisions.

NTR (Nutrien Ltd.) Stock Performance Shows Positive Signs with 2.17% Rise: Potential Undervaluation or Challenges?

On February 1, 2024, the stock performance of NTR (Nutrien Ltd.) showed some positive signs with a 2.17% rise in price since the market last closed. NTR opened at $50.36, which was $0.49 higher than its previous close, indicating some positive sentiment surrounding the stock at the opening of the market. The stock was trading near the bottom of its 52-week range, suggesting potential undervaluation or challenges. Investors and analysts would have closely monitored NTR’s stock throughout the day to assess its future performance.

NTR Stock Performance on February 1, 2024: Mixed Results with Strong Revenue Growth but Decline in Net Income and EPS

NTR Stock Performance on February 1, 2024:

Total Revenue:
– NTR reported a total revenue of $37.88 billion over the past year, a 36.71% increase compared to the previous year.
– However, when compared to the previous quarter’s figure of $5.63 billion, there was a significant decline of 51.68%.

Net Income:
– NTR reported a net income of $7.66 billion over the past year, a substantial increase of 142.94%.
– The net income for the most recent quarter, Q3, stood at $75.00 million, indicating a decline of 82.95% compared to the previous quarter.

Earnings per Share:
– NTR’s EPS over the past year was reported at $14.18, a significant increase of 157.01%.
– The EPS for the most recent quarter, Q3, was reported at $0.15, representing a decline of 82.92% compared to the previous quarter.

Overall, NTR’s stock performance on February 1, 2024, showcased a mixed picture. While the company experienced substantial growth in total revenue, net income, and EPS over the past year, the most recent quarter’s figures indicated a decline across these key financial metrics. Investors should carefully analyze the reasons behind the decline before making investment decisions.

Tags: NTR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Real Estate Investment Markets and money

Analyst Maintains Positive Outlook on DR Horton with Revised Price Target

Corbus Pharmaceuticals Raises Funds for Clinical Development and Faces Market Fluctuations

Diana Shipping Inc Secures Major Time Charter Contract with Nippon Yusen Kabushiki Kaisha

Recommended

Analyst Reaffirms Buy Rating and Price Target for Mayville Engineering

2 years ago
Abeona Therapeut. Stock

Abeona Therapeutics Stock Gains Momentum Following ZEVASKYN™ Launch

7 months ago
General Electric Stock

Is GE Aerospace Flying Too Close to the Sun?

5 months ago
Intel Stock

Leadership Shakeup at Intel Signals Strategic Overhaul

7 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

UnitedHealth Bets on Artificial Intelligence to Counteract Mounting Pressures

A Tale of Two Signals: AppLovin’s Bullish Analysts and Bearish Insiders

Atlassian Shares Hit Fresh Annual Low Amid Sector-Wide Concerns

Institutional Investors Increase Stakes in Healthcare Giant Johnson & Johnson

Qualcomm Launches Major Capital Return Initiative Amid Strategic Shift

Copper’s Critical Role Powers Freeport-McMoRan’s Strategic Expansion

Trending

Rocket Lab USA Stock
Analysis

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

by Kennethcix
March 25, 2026
0

Recent analyst coverage updates for Rocket Lab USA have painted a uniformly optimistic picture for the aerospace...

TSMC Stock

TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest

March 25, 2026
Salesforce Stock

Salesforce Shares Face Pressure from External AI Innovation

March 25, 2026
Unitedhealth Stock

UnitedHealth Bets on Artificial Intelligence to Counteract Mounting Pressures

March 25, 2026
Applovin Stock

A Tale of Two Signals: AppLovin’s Bullish Analysts and Bearish Insiders

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory
  • TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest
  • Salesforce Shares Face Pressure from External AI Innovation

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com